We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Luminex Corporation

Luminex develops, manufactures, and markets biological testing technologies with applications in clinical diagnostics... read more Featured Products: More products

Download Mobile App




Herpesvirus Infection May Increase the Risk of Developing Diabetes

By LabMedica International staff writers
Posted on 30 May 2022

Type 2 diabetes (T2D) is one of the most widespread metabolic diseases, with a 2019 worldwide prevalence estimate of 9. More...

3%, exerting a high mortality burden mainly due to cardiovascular disease.

Herpesviruses are one of the most prevalent viruses in humans, with eight types currently known: herpes simplex viruses (HSV) 1 and 2, varicella-zoster virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV) and human herpesviruses (HHV) 6, 7 and 8. All of them cause lifelong latent infections in their hosts after an initial, usually mild or asymptomatic primary infection.

Medical Scientists at the Ludwig-Maximilians University (Munich, Germany) and their colleagues included in a study group, 962 (49%) men and 999 (51%) women who had had a median age of 54 years at baseline. Incidence analysis for the development of (pre)diabetes used the data for those 1,257 participants with normal glucose tolerance at baseline (median age 49 years, 42% male and 58% female [528 and 729 individuals, respectively]).

Participants with no prior diagnosis of T2D underwent a standard oral glucose tolerance tests (OGTT) with diabetes status assigned using recommended thresholds and measurement of glycated hemoglobin (HbA1c) (a measure of blood sugar control over the previous 3 months). Human herpesvirus serology was determined using multiplex serology, a suspension array-based immunoassay based on recombinant herpesvirus antigens bound to fluorescence-encoded microspheres. Measurements were performed on a Luminex 100 Total System comprising the Luminex 100 analyzer, Luminex XYP plate handler, Luminex SD sheath fluid delivery system (Luminex, Austin, TX, USA).

The investigators reported that the prevalence of prediabetes (impaired fasting glucose [IFG] and impaired glucose tolerance [IGT]) was 27.5% at baseline and 36.2% at follow-up, while T2D was present in 8.5% of participants at baseline and 14.6% at follow-up. Blood testing at the beginning of the study found that EBV was the most prevalent herpesvirus with 98% of the sample group being seropositive, followed by HSV1 (88%), HHV7 (85%), VZV (79%), CMV (46%), HHV6 (39%) and HSV2 (11%). Around one third (34%) tested positive for more viruses at the end of the follow-up period, 54% had the same number, and only 12% were positive for fewer viruses than at the start.

Of the seven herpesviruses examined, HSV2 and CMV were associated with incidence of (pre)diabetes among individuals with normal glucose tolerance at baseline that were independent of other risk factors. Individuals with HSV2 were 59% more likely to develop (pre)diabetes than those who were seronegative, while CMV infection was associated with a 33% increased (pre)diabetes incidence.

The authors concluded that multiplex serology may replace standard ELISA technology, particularly for epidemiologic settings. Applications beyond epidemiology could be the monitoring of infections during pregnancy and the differential diagnosis of infections with similar clinical symptoms. The study was published on May 11, 2022 in the journal Diabetologia.

Related Links:
Ludwig-Maximilians University 
Luminex


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Modular Hemostasis Automation Solution
CN Track
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.